natgillin/translations-raw huggingface dataset:
Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 
Otroke, katerih matere so prejemale antagoniste angiotenzina II, je treba pozorno spremljati zaradi možnosti pojava hipotenzije (glejte poglavji 4.3 in 4.4).
Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnaesemia. 
Tiazidi zvečajo izločanje magnezija s sečem, zato se lahko pojavi hipomagneziemija.
You should discontinue Irbesartan/Hydrochlorothiazide Teva treatment and seek medical attention. 
Prenehajte z jemanjem zdravila Irbesartan/hidroklorotiazid Teva in poiščite zdravniško pomoč.
Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. 
Na podlagi izkušenj z drugimi zdravili, ki zavirajo sistem renin-angiotenzin, domnevamo, da se lahko pri sočasni uporabi antikaliuretičnih diuretikov, pripravkov s kalijem, nadomestkov soli, ki vsebujejo kalij, ali drugih zdravil, ki zvečujejo serumske koncentracije kalija (na primer natrijev heparinat), serumska koncentracija kalija zviša.
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine) The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide; 
Nedepolarizirajoči relaksanti skeletnega mišičja (npr. tubokurarin) Hidroklorotiazid lahko potencira delovanje nedepolarizirajočih relaksantov skeletnega mišičja.
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. 
Pri bolnikih s primarnim aldosteronizmom zdravljenje z antihipertenzivi, ki zavirajo sistem renin-angiotenzin, običajno ni učinkovito.
For therapeutic doses of irbesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. 
Pri terapevtskih odmerkih irbesartana pri ljudeh ne kaže, da bi bila hiperplazija/hipertrofija jukstaglomerulnih celic kakorkoli pomembna.
Adverse reactions reported with the use of hydrochorothiazide alone Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Neželeni učinki, o katerih so poročali pri uporabi hidroklorotiazida samega Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. 
Tiazidi lahko zmanjšajo izločanje kalcija s sečem in povzročijo občasno in blago zvečanje njegove serumske vrednosti v odsotnosti motenj presnove kalcija.
Non-steroidal anti-inflammatory drugs 
Nesteroidna protivnetna zdravila
Renal impairment and kidney transplantation 
Ledvična okvara in presaditev ledvic
Irbesartan does not require metabolic activation for its activity. 
Irbesartan za svoje delovanje ne potrebuje presnovne aktivacije.
What Irbesartan/Hydrochlorothiazide Teva is and what it is used for What you need to know before you take Irbesartan/Hydrochlorothiazide Teva How to take Irbesartan/Hydrochlorothiazide Teva Possible side effects 
Kaj je zdravilo Irbesartan/hidroklorotiazid Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Irbesartan/hidroklorotiazid Teva Kako jemati zdravilo Irbesartan/hidroklorotiazid Teva
If you get any of these symptoms or get short of breath, stop taking Irbesartan/Hydrochlorothiazide Teva and contact your doctor immediately. 
Če opazite katerega koli od teh simptomov ali če se pojavi občutek težkega dihanja, zdravilo Irbesartan/hidroklorotiazid Teva takoj prenehajte jemati in nemudoma poiščite zdravniško pomoč.
Diuretic agents such as the hydrochlorothiazide contained in Irbesartan/Hydrochlorothiaizde Teva may have an effect on other medicines. 
Diuretiki, med katere spada tudi hidroklorotiazid, ki ga vsebuje zdravilo Irbesartan/hidroklorotiazid Teva, lahko vplivajo na delovanje drugih zdravil.
Aluminium - Aluminium blisters: This medicinal product does not require any special storage conditions. 
Aluminij - aluminijevi pretisni omoti: Za shranjevanje zdravila niso potreba posebna navodila.
Pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters. 
Pakiranja po 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 in 100 filmsko obloženih tablet v neperforiranem pretisnem omotu.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
potassium supplements salt substitutes containing potassium potassium sparing medicines or other diuretics (water tablets) some laxatives medicines for the treatment of gout therapeutic vitamin D supplements medicines to control heart rhythm medicines for diabetes (oral agents or insulins) carbamazepine (a medicine for the treatment of epilepsy). 
pripravke s kalijem nadomestke soli, ki vsebujejo kalij zdravila, ki varčujejo s kalijem ali druge diuretike (tablete za odvajan zdravila za zdravljenje protina dodatke vitamina D zdravila za uravnavanje srčnega ritma zdravila za zdravljenje sladkorne bolezni (peroralni pripravki ali insulin) karbamazepin (zdravilo za zdravljenje epilepsije)
Do not use this medicine after the expiry date that is stated on the carton and on the blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Alcohol Potentiation of orthostatic hypotension may occur; 
Pojavi se lahko ortostatska hipotenzija.
Following oral administration of irbesartan/hydrochlorothiazide, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively. 
Po peroralnem jemanju kombinacije irbesartana in hidroklorotiazida je biološka uporabnost irbesartana približno 60-80 %, hidroklorotiazida pa 50-80 %.
No teratogenic effects were observed in the rat or rabbit. 
Teratogenih učinkov pri podganah ali kuncih niso opazili.
Since Irbesartan/Hydrochlorothiazide Teva contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. 
Ker zdravilo Irbesartan/hidroklorotiazid Teva vsebuje hidroklorotiazid, se njegova uporaba v prvem trimesečju nosečnosti ne priporoča.
Increase in dosage of probenecid or sulfinpyrazone may be necessary. 
Odmerek probenecida ali sulfinpirazona je treba po potrebi zvečati.
The recommended dose of Irbesartan/Hydrochlorothiazide Teva is one tablet a day. 
Priporočeni odmerek zdravila Irbesartan/hidroklorotiazid Teva je ena tableta na dan.
The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. 
Antihipertenzijski učinek obeh učinkovin je aditiven in zvišan krvni tlak se zniža bolj kot po jemanju samo ene od učinkovin.
Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. 
Dnevni odmerki, večji od 300 mg irbesartana/25 mg hidroklorotiazida, niso priporočeni.
Indigotine (Indigo carmine aluminium lake FD&C blue #2) Iron Oxide Black 
rdeči železov oksid indigotin (indigo karmin aluminijevo rdeče FD&C modro #2)
The effects of the irbesartan/hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone. 
Vpliva kombinirane uporabe irbesartana in hidroklorotiazida na plodnost v študijah na živalih niso ugotavljali, kajti neželenih učinkov na plodnost bodisi irbesartana bodisi hidroklorotiazida pri živalih in ljudeh niso dokazali.
The other side of the tablet debossed with the number "7469". 
Na drugi strani tablete je vtisnjena številka "7469".
Thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4); 
Tiazidi, ki povzročajo hipokaliemijo ali hipomagneziemijo, lahko sprožijo z digitalisom inducirano srčno aritmijo (glejte poglavje 4.4).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Irbesartan/hidroklorotiazid Teva Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide (range: 37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients experienced adverse reactions. 
Med 898 bolniki s hipertenzijo, ki so v s placebom nadzorovanih študijah prejemali različne odmerke kombinacije irbesartan/hidroklortiazid (razpon: 37,5 mg/6,25 mg do 300 mg/25 mg), je 29,5 %
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history. 
Preobčutljivostne reakcije na hidroklorotiazid se lahko pojavijo tako pri bolnikih, ki imajo v anamnezi podatek o alergiji ali bronhialni astmi, kot pri tistih, ki ju še niso imeli; pogosteje pa se pojavijo pri tistih, ki so alergijo ali bronhialno astmo že imeli.
Irbesartan/Hydrochlorothiazide Teva can be taken once daily, with or without food. 
Odmerjanje Zdravilo Irbesartan/hidroklorotiazid Teva se lahko jemlje enkrat na dan skupaj s hrano ali brez nje.
Anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria 
Bolezni kože in podkožja neznana anafilaktične reakcije, toksična epidermalna nekroliza nekrotizirajoči angiitis (vaskulitis, vnetje kožnih žil ali mezgovnic), reakcije, podobne kožnemu eritematoznemu lupusu, reaktivacija kožnega eritematoznega lupusa, fotosenzitivne reakcije,
The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. 
Zaradi diuretskega delovanja hidroklorotiazida se zmanjša prostornina plazme ter zvečata aktivnost renina in izločanje aldosterona; posledično se zveča izguba kalija in hidrogenkarbonata v seču ter zmanjša serumska koncentracija kalija.
If you take more Irbesartan/Hydrochlorothiazide Teva than you should 
Če ste vzeli večji odmerek zdravila Irbesartan/hidroklorotiazid Teva, kot bi smeli
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/ 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA)
Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. 
V študijah pri živalih so v zarodkih podgan in kunčjih samic odkrili z radioaktivnim izotopom označen irbesartan.
When angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. 
Pri sočasnem zdravljenju z antagonisti angiotenzina II in nesteroidnimi protivnetnimi zdravili (NSAID) (npr. selektivnimi COX-2 zaviralci, acetilsalicilno kislino (> 3 g/dan) in neselektivnimi
Irbesartan/Hydrochlorothiazide Teva is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure. 
Zdravilo Irbesartan/hidroklorotiazid Teva uporabljamo za zdravljenje zvišanega krvnega tlaka, če pri zdravljenju samo z irbesartanom ali samo s hidroklorotiazidom krvni tlak ni bil zadostno nadzorovan.
Irbesartan/Hydrochlorothiazide Teva should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3). 
Zdravilo Irbesartan/hidroklorotiazid Teva se pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) ne sme uporabljati (glejte poglavje 4.3).
Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers. 
Uporaba irbesartana in hidroklorotiazida, pri odmerkih do 300 mg irbesartana/25 mg hidroklorotazida, je pri bolnikih, ki dobivajo še druge antihipertenzive, tudi blokatorje kalcijevih kanalčkov in adrenergičnih receptorjev beta, varna.
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥ 30 ml/min (see sections 4.3 and 4.4). 
Pri bolnikih z ledvično okvaro, pri katerih je ledvični očistek kreatinina ≥ 30 ml/min prilagoditev odmerka ni potrebna (glejte poglavji 4.3 in 4.4).
Not known 
neznana
What Irbesartan/Hydrochlorothiazide Teva is and what it is used for 
Kaj je zdravilo Irbesartan/hidroklorotiazid Teva in za kaj ga uporabljamo
In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. 
Pri bolnikih z ledvično okvaro in pri tistih na hemodializi farmakokinetični parametri irbesartana niso bistveno spremenjeni.
In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. 
Pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. 
Priporočeno je individualno prilagajanje odmerka posameznih učinkovin (irbesartana in hidroklorotiazida).
Depression, sleep disturbances 
Psihiatrične motnje neznana depresija, motnje spanja
Irbesartan/Hydrochlorothiazide Teva is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Zdravila Irbesartan/hidroklorotiazid Teva ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
However, occasionally dizziness or weariness may occur during treatment of high blood pressure. 
Med zdravljenjem zvišanega krvnega tlaka se lahko občasno pojavi omotica ali utrujenost.
The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides. 
Tiazidni diuretiki lahko zvečajo hiperglikemični učinek blokatorjev beta in diazoksida.
However, there was no difference in the half-life and accumulation of irbesartan. 
Razlik pri razpolovnem času in kopičenju ni.
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. 
V študijah na živalih so ugotovili pojav prehodnih toksičnih učinkov (zvečano votlino ledvičnega meha, hidroureter ali podkožni edem) pri plodovih podgan, ki pa so po rojstvu izginili.
Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. 
Irbesartan se presnavlja v jetrih s konjugacijo z glukuronsko kislino in z oksidacijo.
Your doctor will normally advise you to stop taking Irbesartan/Hydrochlorothiazide Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan/Hydrochlorothiazide Teva. 
Zdravnik vam bo pravilom svetoval, da zdravljenje z zdravilom Irbesartan/hidroklorotiazid Teva prekinete še preden zanosite ali takoj, ko se izkaže, da ste zanosili in vam predpisal zdravljenje z drugim zdravilom.
While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure glaucoma have been reported so far with hydrochlorothiazide. 
Hidroklorotiazid je sicer sulfonamid, vendar pa so do sedaj med njegovo uporabo poročali le o posameznih primerih akutnega glavkoma z zaprtim zakotjem.
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution. 
Bolnikom z ledvično okvaro, pri katerih je ledvični očistek ≥ 30 ml/min odmerka zdravila ni treba prilagajati, kljub temu pa je treba tistim z blago ali zmerno ledvično okvaro (očistek kreatinina ≥ 30 ml/min, toda < 60 ml/min) dajati kombinirano zdravilo zelo previdno.
White opaque PVC-PVdC - Aluminium blisters or Aluminium - Aluminium blisters. 
Beli prozorni PVC-PVdC - aluminijevi pretisni omoti ali aluminij - aluminijevi pretisni omoti.
Film-coated tablet. 
FARMACEVTSKA OBLIKA Filmsko obložene tablete.
Lithium The combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.5). 
Litij Kombinacija litija in zdravila Irbesartan/hidroklorotiazid Teva ni priporočena (glejte poglavje 4.5).
Twelve percent (12 %) of patients were diabetic, 34 % were hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5 % of the participants. 
Najpogostejša bolezen srca je bila stabilna angina pektoris, ki jo je imelo 3,5 % vključenih bolnikov.
These findings appear to have no relevance to the use of therapeutic doses of irbesartan/hydrochlorothiazide in humans. 
Ugotovitve pa ne veljajo za terapevtske odmerke irbesartana/hidroklorotiazida pri ljudeh.
Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan with or without thiazide diuretics unless the volume depletion is corrected first (see section 4.4). 
Na začetku zdravljenja z irbesartanom in tiazidnimi diuretiki ali brez njih se lahko zaradi predhodnega zdravljenja z velikimi odmerki diuretikov in posledično zmanjšanega intravaskularnega volumna zveča nevarnost pojava hipotenzije, če predhodno nismo popravili intravaskularnega volumna (glejte poglavje 4.4).
No significant effects on the number of corpora lutea, implants, or live foetuses were observed. 
Pomembnih učinkov na število rumenih telesc, nidacijo ali preživetje zarodkov niso opazili.
TEVA UK Ltd Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG United Kingdom 
Eastbourne East Sussex BN22 9AG
Medicinal products affecting potassium 
Zdravila, ki vplivajo na kalij
The other side of the tablet debossed with the number "7238". 
Na drugi strani tablete je vtisnjena številka "7238".
How to store Irbesartan/Hydrochlorothiazide Teva Contents of the pack and other information 
Shranjevanje zdravila Irbesartan/hidroklorotiazid Teva Vsebina pakiranja in dodatne informacije
Common side effects (may affect up to 1 in 10 people): nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine). 
siljenje na bruhanje/bruhanje nenormalno uriniranje utrujenost omotica (tudi pri vstajanju iz ležečega ali sedečega položaja)krvne preiskave lahko pokažejo zvišanje vrednosti encima, ki kaže na delovanje mišic in srca (encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
Irbesartan/Hydrochlorothiazide Teva is a combination of two active substances, irbesartan and hydrochlorothiazide. 
Irbesartan/hidroklorotiazid Teva je kombinacija dveh učinkovin, irbesartana in hidroklorotiazida.
The active ingredients are irbesartan and hydrochlorothiazide. 
Učinkovini sta irbesartan in hidroklorotiazid.
A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy. 
Že pred načrtovano nosečnostjo je treba izbrati drugo primerno zdravilo.
For Irbesartan/Hydrochlorothiazide Teva packaged in aluminium - aluminium blisters: This medicinal product does not require any special storage conditions. 
Za zdravilo Irbesartan/hidroklorotiazid Teva v aluminij - aluminijevih pretisnih omotih: : Za shranjevanje zdravila niso potrebna posebnia navodila.
For Irbesartan/Hydrochlorothiazide Teva packaged in white opaque PVC-PVdC - aluminium blisters: Do not store above 30°C. 
Za zdravilo Irbesartan/hidroklorotiazid Teva v belih neprozornih PVC-PVdC - aluminijevih pretisnih omotih: Shranjujte pri temperaturi do 30°C.
Irbesartan/Hydrochlorothiazide Teva is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Irbesartan/hidroklorotiazid Teva ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis. 
hipokloremija, hiponatriemija) in dehidracija, ki sta posledica čezmerne diureze.
Latent diabetes mellitus may become manifest during thiazide therapy. 
Med zdravljenjem s tiazidnimi diuretiki se lahko latentni diabetes mellitus spremeni v manifestnega.
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed): 
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe:
Thiazide therapy may impair glucose tolerance. 
Tiazidni diuretiki lahko zmanjšajo toleranco za glukozo.
White opaque PVC-PVdC - Aluminium blisters: Do not store above 30°C. 
Beli neprozorni PVC-PVdC - aluminijevi pretisni omoti: Shranjujte pri temperaturi do 30°C.
You should also tell your doctor: 
Posvetujte se tudi,
Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter. 
Bolniki morajo uživati primerno količino tekočine in po uvedbi sočasne uporabe je priporočljivo redno spremljanje delovanja ledvic.
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
• sočasna uporaba zdravila Irbesartan/hidroklorotiazid Teva in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (hitrost glomerularne filtracije < 60 ml/min/1,73 m2) (glejte poglavji 4.5 in 5.1).
Irbesartan/Hydrochlorothiazide Teva is not recommended for use in children and adolescents because the safety and efficacy have not been established. 
Varnost in učinkovitost zdravila Irbesartan/hidroklorotiazid Teva nista bili dokazani, zato uporaba pri otrocih in mladostnikih ni priporočljiva.
Uncommon side effects (may affect up to 1 in 100 people): diarrhoea low blood pressure fainting heart rate increased flushing swelling sexual dysfunction (problems with sexual performance) blood tests may show lowered levels of potassium and sodium in your blood. 
driska nizek krvni tlak omedlevica hiter srčni utrip zardevanje otekline spolne motnje (težave pri spolnih odnosih)krvne preiskave lahko pokažejo znižane vrednosti kalija in natrija v krvi.
The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). 
Uporaba antagonistov angiotenzina II v prvem trimesečju nosečnosti ni priporočljiva (glejte poglavje 4.4).